```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page for STN Seminar Schedule - N. America
 NEWS  2  JUL 02   LMEDLINE coverage updated
 NEWS  3  JUL 02   SCISEARCH enhanced with complete author names
 NEWS  4  JUL 02   CHEMCATS accession numbers revised
 NEWS  5  JUL 02   CA/CAplus enhanced with utility model patents from China
 NEWS  6  JUL 16   CAplus enhanced with French and German abstracts
 NEWS  7  JUL 18   CA/CAplus patent coverage enhanced
 NEWS  8  JUL 26   USPATFULL/USPAT2 enhanced with IPC reclassification
 NEWS  9  JUL 30   USGENE now available on STN
 NEWS 10  AUG 06   CAS REGISTRY enhanced with new experimental property tags
 NEWS 11  AUG 06   BEILSTEIN updated with new compounds
 NEWS 12  AUG 06   FSTA enhanced with new thesaurus edition
 NEWS 13  AUG 13   CA/CAplus enhanced with additional kind codes for granted
                   patents
 NEWS 14  AUG 20   CA/CAplus enhanced with CAS indexing in pre-1907 records
 NEWS 15  AUG 27   Full-text patent databases enhanced with predefined
                   patent family display formats from INPADOCDB
 NEWS 16  AUG 27   USPATOLD now available on STN
 NEWS 17  AUG 28   CAS REGISTRY enhanced with additional experimental
                   spectral property data
 NEWS 18  SEP 07   STN AnaVist, Version 2.0, now available with Derwent
                   World Patents Index
 NEWS 19  SEP 13   FORIS renamed to SOFIS
 NEWS 20  SEP 13   INPADOCDB enhanced with monthly SDI frequency
 NEWS 21  SEP 17   CA/CAplus enhanced with printed CA page images from
                   1967-1998
 NEWS 22  SEP 17   CAplus coverage extended to include traditional medicine
                   patents
 NEWS 23  SEP 24   EMBASE, EMBAL, and LEMBASE reloaded with enhancements

 NEWS EXPRESS  19 SEPTEMBER 2007:  CURRENT WINDOWS VERSION IS V8.2,
               CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *
```

```
FILE 'HOME' ENTERED AT 15:58:12 ON 01 OCT 2007

=> file medline, uspatful, dgene, embase, biosis, wpids
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                0.21       0.21

FILE 'MEDLINE' ENTERED AT 15:58:46 ON 01 OCT 2007

FILE 'USPATFULL' ENTERED AT 15:58:46 ON 01 OCT 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 15:58:46 ON 01 OCT 2007
COPYRIGHT (C) 2007 THE THOMSON CORPORATION

FILE 'EMBASE' ENTERED AT 15:58:46 ON 01 OCT 2007
Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 15:58:46 ON 01 OCT 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'WPIDS' ENTERED AT 15:58:46 ON 01 OCT 2007
COPYRIGHT (C) 2007 THE THOMSON CORPORATION

=> s (compound and kringle 5)
L1          433 (COMPOUND AND KRINGLE 5)

=> s l1 and (lysyl-leucyl-tyrosyl-aspartyl)
L2            6 L1 AND (LYSYL-LEUCYL-TYROSYL-ASPARTYL)

=> d l2 ti abs ibib tot

L2   ANSWER 1 OF 6  USPATFULL on STN
TI     Novel antiangiogenic peptides, polypeptides encoding same and methods
       for inhibiting angiogenesis
AB     Mammalian kringle 5 fragments and kringle
       5 fusion proteins are disclosed as a compounds for treating
       angiogenic diseases. Methods and compositions for inhibiting angiogenic
       diseases are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER:        2004:178957  USPATFULL
TITLE:                   Novel antiangiogenic peptides, polypeptides encoding
                         same and methods for inhibiting angiogenesis
INVENTOR(S):             Davidson, Donald J., Gurnee, IL, UNITED STATES
                         Wang, Jieyi, Gurnee, IL, UNITED STATES
                         Gubbins, Earl J., Libertyville, IL, UNITED STATES

                              NUMBER         KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 2004138127      A1   20040715
APPLICATION INFO.:       US 2004-753646     A1   20040108  (10)
RELATED APPLN. INFO.:    Continuation of Ser. No. US 1997-924287, filed on 5 Sep
                         1997, GRANTED, Pat. No. US 6699838 Continuation-in-part
                         of Ser. No. US 1997-851350, filed on 5 May 1997,
                         GRANTED, Pat. No. US 6057122 Continuation-in-part of
                         Ser. No. US 1997-832087, filed on 3 Apr 1997, GRANTED,
                         Pat. No. US 5981484 Continuation-in-part of Ser. No. US
                         1996-643219, filed on 3 May 1996, GRANTED, Pat. No. US
                         5801146
DOCUMENT TYPE:           Utility
FILE SEGMENT:            APPLICATION
LEGAL REPRESENTATIVE:    STEVEN F. WEINSTOCK, ABBOTT LABORATORIES, 100 ABBOTT
```

PARK ROAD, DEPT. 377/AP6A, ABBOTT PARK, IL, 60064-6008
NUMBER OF CLAIMS: 68
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Page(s)
LINE COUNT: 3457
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 2 OF 6 USPATFULL on STN
TI Antiangiogenic peptides
AB Mammalian kringle 5 fragments and kringle 5 fusion proteins are disclosed as a compounds for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:53363 USPATFULL
TITLE: Antiangiogenic peptides
INVENTOR(S): Davidson, Donald J., Gurnee, IL, United States
PATENT ASSIGNEE(S): Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6699838	B1	20040302
APPLICATION INFO.:	US 1997-924287		19970905 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-851350, filed on 5 May 1997, now patented, Pat. No. US 6057122 Continuation-in-part of Ser. No. US 1997-832087, filed on 3 Apr 1997, now patented, Pat. No. US 5981484 Continuation-in-part of Ser. No. US 1996-643219, filed on 3 May 1996, now patented, Pat. No. US 5801146
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Low, Christopher S. F.
ASSISTANT EXAMINER: Robinson, Hope A.
LEGAL REPRESENTATIVE: Casuto, Dianne, Steele, Gregory W.
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 3178
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 3 OF 6 USPATFULL on STN
TI Antiangiogenic peptides and methods for inhibiting angiogenesis
AB Mammalian kringle 5 fragments are disclosed as a compounds for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2001:97890 USPATFULL
TITLE: Antiangiogenic peptides and methods for inhibiting angiogenesis
INVENTOR(S): Davidson, Donald J., Gurnee, IL, United States
PATENT ASSIGNEE(S): Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6251867	B1	20010626
APPLICATION INFO.:	US 1998-132154		19980811 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-132154, filed on 11 Aug 1998 And Ser. No. US 1997-832087, filed on 3 Apr 1997 Continuation-in-part of Ser. No. US 1996-643219, filed on 3 May 1996, now patented, Pat. No. US 5801146

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Hendricks, Keith D.
ASSISTANT EXAMINER: Stole, Einar
LEGAL REPRESENTATIVE: Steele, Gregory W., Casuto, Dianne
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 12 Drawing Page(s)
LINE COUNT: 2101
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 4 OF 6 USPATFULL on STN
TI Antiangiogenic peptides polynucleotides encoding same and methods for inhibiting angiogenesis
AB Mammalian kringle 5 fragments and kringle 5 fusion proteins are disclosed as a compounds for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2000:53906 USPATFULL
TITLE: Antiangiogenic peptides polynucleotides encoding same and methods for inhibiting angiogenesis
INVENTOR(S): Davidson, Donald J., Gurnee, IL, United States
PATENT ASSIGNEE(S): Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6057122		20000502
APPLICATION INFO.:	US 1997-851350		19970505 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-832087, filed on 3 Apr 1997 which is a continuation-in-part of Ser. No. US 1996-643219, filed on 3 May 1996, now patented, Pat. No. US 5801146
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wax, Robert A.
ASSISTANT EXAMINER: Stole, Einar
LEGAL REPRESENTATIVE: Steele, Gregory W., Casuto, Dianne
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 3215
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 5 OF 6 USPATFULL on STN
TI Antiangiogenic peptides and methods for inhibiting angiogenesis
AB Mammalian kringle 5 peptide fragments are disclosed for treating angiogenic diseases Methods and compositions for inhibiting angiogenic diseases are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 1999:141891 USPATFULL
TITLE: Antiangiogenic peptides and methods for inhibiting angiogenesis
INVENTOR(S): Davidson, Donald J., Gurnee, IL, United States
PATENT ASSIGNEE(S): Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5981484		19991109
APPLICATION INFO.:	US 1997-832087		19970403 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1996-643219, filed on 3 May 1996, now patented, Pat. No. US 5801146
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Prouty, Rebecca E.
ASSISTANT EXAMINER: Stole, Einar
LEGAL REPRESENTATIVE: Steele, Gregory W., Casuto, Dianne
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 12 Drawing Page(s)
LINE COUNT: 2474
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 6 OF 6 USPATFULL on STN
TI Antiangiogenic peptides and methods for inhibiting angiogenesis
AB Mammalian kringle 5 fragments are disclosed as a compounds for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 1999:132781 USPATFULL
TITLE: Antiangiogenic peptides and methods for inhibiting angiogenesis
INVENTOR(S): Davidson, Donald J., Gurnee, IL, United States
PATENT ASSIGNEE(S): Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5972896		19991026
APPLICATION INFO.:	US 1998-131995		19980811 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1997-832087, filed on 3 Apr 1997 which is a continuation-in-part of Ser. No. US 1996-643219, filed on 3 May 1996, now patented, Pat. No. US 5801146
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wax, Robert A.
ASSISTANT EXAMINER: Stole, Einar
LEGAL REPRESENTATIVE: Steele, Gregory W., Casuto, Dianne
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 12 Drawing Page(s)
LINE COUNT: 2444
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 15:58:12 ON 01 OCT 2007)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, BIOSIS, WPIDS' ENTERED AT 15:58:46 ON 01 OCT 2007
L1 433 S (COMPOUND AND KRINGLE 5)
L2 6 S L1 AND (LYSYL-LEUCYL-TYROSYL-ASPARTYL)

=> s l1 and (arginyl or I-tyrosyl or phenylalnyl)
L3 19 L1 AND (ARGINYL OR I-TYROSYL OR PHENYLALNYL)

=> d l3 ti abs ibib tot

L3 ANSWER 1 OF 19 USPATFULL on STN
TI OPTIMIZED ANTI-CD30 ANTIBODIES
AB An antibody that targets CD30, wherein the antibody comprises at least

one modification relative to a parent antibody and the antibody binds with altered affinity to an FcγR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the anti-CD30 antibody.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2007:190130 USPATFULL
TITLE: OPTIMIZED ANTI-CD30 ANTIBODIES
INVENTOR(S): Lazar, Gregory Alan, Arcadia, CA, UNITED STATES
Desjarlais, John R., Pasadena, CA, UNITED STATES
Hammond, Philip W., Sierra Madre, CA, UNITED STATES
Carmichael, David F., Monrovia, CA, UNITED STATES
Chen, Bao-lu, San Ramon, CA, UNITED STATES
Chu, Seung Y., Upland, CA, UNITED STATES
Karki, Sher Bahadur, Ponoma, CA, UNITED STATES
PATENT ASSIGNEE(S): Xencor, Inc., Monrovia, CA, UNITED STATES, 91016 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007166309	A1	20070719
APPLICATION INFO.:	US 2007-686853	A1	20070315 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2006-544165, filed on 6 Oct 2006, PENDING Continuation-in-part of Ser. No. US 2004-4590, filed on 3 Dec 2004, PENDING Continuation-in-part of Ser. No. US 2005-124620, filed on 5 May 2005, PENDING Continuation-in-part of Ser. No. US 2004-822231, filed on 26 Mar 2004, PENDING Continuation-in-part of Ser. No. US 2003-672280, filed on 26 Sep 2003, PENDING Continuation-in-part of Ser. No. US 2003-379392, filed on 3 Mar 2003, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-776598P	20060224 (60)
	US 2005-737998P	20051118 (60)
	US 2005-724624P	20051006 (60)
	US 2005-750697P	20051215 (60)
	US 2006-745536P	20060425 (60)
	US 2004-568440P	20040715 (60)
	US 2004-589906P	20040720 (60)
	US 2004-627026P	20041109 (60)
	US 2004-626991P	20041110 (60)
	US 2004-627774P	20041112 (60)
	US 2003-442301P	20030123 (60)
	US 2003-467606P	20030502 (60)
	US 2003-477839P	20030612 (60)
	US 2002-414443P	20020930 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MORGAN, LEWIS & BOCKIUS, LLP, ONE MARKET SPEAR STREET TOWER, SAN FRANCISCO, CA, 94105, US
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1-24
NUMBER OF DRAWINGS: 30 Drawing Page(s)
LINE COUNT: 5275
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 2 OF 19 USPATFULL on STN
TI Optimized proteins that target Ep-CAM
AB Humanized Ep-CAM-targeting antibodies and methods of making and using the same are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2007:184790 USPATFULL
TITLE: Optimized proteins that target Ep-CAM
INVENTOR(S): Barbosa, Maria D., San Dimas, CA, UNITED STATES
Chamberlain, Aaron K., Pasadena, CA, UNITED STATES
Desjarlais, John R., Pasadena, CA, UNITED STATES
PATENT ASSIGNEE(S): XENCOR, INC. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007161783	A1	20070712
APPLICATION INFO.:	US 2006-484183	A1	20060710 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-745078P	20060418 (60)
	US 2006-779961P	20060306 (60)
	US 2005-741966P	20051202 (60)
	US 2005-697768P	20050708 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MORGAN, LEWIS & BOCKIUS, LLP, ONE MARKET SPEAR STREET TOWER, SAN FRANCISCO, CA, 94105, US
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 44 Drawing Page(s)
LINE COUNT: 7641
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 3 OF 19 USPATFULL on STN
TI Optimized anti-CD30 antibodies
AB An antibody that targets CD30, wherein the antibody comprises at least one modification relative to a parent antibody and the antibody binds with altered affinity to an FcγR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the anti-CD30 antibody.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2007:169491 USPATFULL
TITLE: Optimized anti-CD30 antibodies
INVENTOR(S): Lazar, Gregory Alan, Arcadia, CA, UNITED STATES
Desjarlais, John R., Pasadena, CA, UNITED STATES
Hammond, Philip W., Sierra Madre, CA, UNITED STATES
Carmichael, David F., Monrovia, CA, UNITED STATES
Chen, Bao-lu, San Ramon, CA, UNITED STATES
Chu, Seung Y., Upland, CA, UNITED STATES
Karki, Sher Bahadur, Ponoma, CA, UNITED STATES
PATENT ASSIGNEE(S): XENCOR, INC., Monrovia, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007148171	A1	20070628
APPLICATION INFO.:	US 2006-544165	A1	20061006 (11)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2004-4590, filed on 3 Dec 2004, PENDING Continuation-in-part of Ser. No. US 2005-124620, filed on 5 May 2005, PENDING Continuation-in-part of Ser. No. US 2004-822231, filed on 26 Mar 2004, PENDING Continuation-in-part of Ser. No. US 2003-672280, filed on 26 Sep 2003, PENDING Continuation-in-part of Ser. No. US 2003-379392, filed on 3 Mar 2003, ABANDONED

	NUMBER	DATE

PRIORITY INFORMATION: US 2006-776598P 20060224 (60)
US 2005-737998P 20051118 (60)
US 2005-724624P 20051006 (60)
US 2005-750697P 20051215 (60)
US 2006-745536P 20060425 (60)
US 2004-568440P 20040715 (60)
US 2004-589906P 20040720 (60)
US 2004-627026P 20041109 (60)
US 2004-626991P 20041110 (60)
US 2004-627774P 20041112 (60)
US 2003-442301P 20030123 (60)
US 2003-467606P 20030502 (60)
US 2003-477839P 20030612 (60)
US 2002-414443P 20020930 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MORGAN, LEWIS & BOCKIUS, LLP, ONE MARKET SPEAR STREET TOWER, SAN FRANCISCO, CA, 94105, US
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 30 Drawing Page(s)
LINE COUNT: 5264
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 4 OF 19 USPATFULL on STN
TI Optimized proteins that target Ep-CAM
AB Humanized Ep-CAM-targeting antibodies and methods of making and using the same are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2007:140415 USPATFULL
TITLE: Optimized proteins that target Ep-CAM
INVENTOR(S): Chamberlain, Aaron K., Pasadena, CA, UNITED STATES
Desjarlais, John R., Pasadena, CA, UNITED STATES
Lazar, Gregory Alan, Arcadia, CA, UNITED STATES
PATENT ASSIGNEE(S): XENCOR, INC. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2007122406	A1	20070531	
APPLICATION INFO.:	US 2006-484198	A1	20060710	(11)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2006-745078P	20060418	(60)
	US 2006-779961P	20060306	(60)
	US 2005-741966P	20051202	(60)
	US 2005-697768P	20050708	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MORGAN, LEWIS & BOCKIUS, LLP, ONE MARKET SPEAR STREET TOWER, SAN FRANCISCO, CA, 94105, US
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 44 Drawing Page(s)
LINE COUNT: 7660
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 5 OF 19 USPATFULL on STN
TI Human kininogen D3 domain polypeptide as an anti-angiogenic and anti-tumor agent
AB Human kininogen domain 3 (HK-D3) polypeptides and biologically active variants and derivatives of HK-D3 are anti-angiogenic. These molecules are used to inhibit angiogenesis or treat a disease or condition in

which angiogenesis is pathogenic.. Because of their anti-angiogenic potential, these molecules compounds are useful in the treatment of cancer by inhibiting or reversing the growth of primary or metastatic tumors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2006:188185 USPATFULL
TITLE:	Human kininogen D3 domain polypeptide as an anti-angiogenic and anti-tumor agent
INVENTOR(S):	Donate, Fernando, San Diego, CA, UNITED STATES Mazar, Andrew P., San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006159620	A1	20060720
	US 7119069	B2	20061010
APPLICATION INFO.:	US 2006-387840	A1	20060324 (11)

RELATED APPLN. INFO.: Division of Ser. No. US 2003-661784, filed on 15 Sep 2003, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-410279P	20020913 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	MCKENNA LONG & ALDRIDGE LLP, 1900 K Street, N.W., Washington, DC, 20006, US
NUMBER OF CLAIMS:	20
EXEMPLARY CLAIM:	1-42
NUMBER OF DRAWINGS:	8 Drawing Page(s)
LINE COUNT:	2511

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 6 OF 19 USPATFULL on STN

TI Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use

AB Crosslinkable compositions are provided that readily crosslink in situ to provide crosslinked biomaterials. The composition contains at least two biocompatible, non-immunogenic components having reactive groups thereon, with the functional groups selected so as to enable inter-reaction between the components, i.e., crosslinking. In one embodiment, a first component has nucleophilic groups and a second component has electrophilic groups. Additional components may have nucleophilic or electrophilic groups. Methods for preparing and using the compositions are also provided as are kits for delivery of the compositions. Exemplary uses for the crosslinked compositions include tissue augmentation, biologically active agent delivery, bioadhesion, and prevention of adhesions following surgery or injury.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2005:323977 USPATFULL
TITLE:	Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
INVENTOR(S):	Daniloff, George Y., Mountain View, CA, UNITED STATES Sehl, Louis C., Redwood City, CA, UNITED STATES Trollsas, Olof Mikael, San Jose, CA, UNITED STATES Schroeder, Jacqueline, Boulder Creek, CA, UNITED STATES Gravett, David M., Vancouver, CANADA Toleikis, Philip M., Vancouver, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005281883	A1	20051222

APPLICATION INFO.: US 2005-118088 A1 20050428 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-566569P	20040428 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: REED INTELLECTUAL PROPERTY LAW GROUP, 1400 PAGE MILL ROAD, PALO ALTO, CA, 94304-1124, US
NUMBER OF CLAIMS: 349
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 8347
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 7 OF 19 USPATFULL on STN
TI Cell surface tropomyosin as a target of angiogenesis inhibition
AB The present invention is directed to novel methods for inhibiting angiogenesis and treating tumors and cancer by targeting tropomyosin (Tpm) expressed on the surface of endothelial cells and/or tumor cells, to Tpm polypeptides and peptides, as well as variants and derivatives thereof that bind inhibitors of angiogenesis, and to anti-Tpm antibodies that block or stimulate angiogenesis. Cyclic peptides that bind to the D5 subunit of HK.sub.a and inhibit angiogenesis are also included. Method for screening test compounds as candidate antiangiogenic molecule that binds to Tpm are disclosed, as are affinity ligands comprising the proteins, peptides, variants and derivatives of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2005:145053 USPATFULL
TITLE: Cell surface tropomyosin as a target of angiogenesis inhibition
INVENTOR(S): McCrae, Keith, Pepper Pike, OH, UNITED STATES
Donate, Fernando, San Diego, CA, UNITED STATES
Juarez, Jose, San Diego, CA, UNITED STATES
Mazar, Andrew P., San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005124794	A1	20050609	
APPLICATION INFO.:	US 2003-507734	A1	20030317	(10)
	WO 2003-US8060		20030317	

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-364047P	20020315 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MCKENNA LONG & ALDRIDGE LLP, 1900 K STREET, NW, WASHINGTON, DC, 20006, US
NUMBER OF CLAIMS: 63
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Page(s)
LINE COUNT: 4919
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 8 OF 19 USPATFULL on STN
TI Human kininogen D3 domain polypeptide as an anti-angiogenic and anti-tumor agent
AB Human kininogen domain 3 (HK-D3) polypeptides and biologically active variants and derivatives of HK-D3 are anti-angiogenic. These molecules are used to inhibit angiogenesis or treat a disease or condition in which angiogenesis is pathogenic. Because of their anti-angiogenic potential, these molecules are useful in the treatment of cancer by

inhibiting or reversing the growth of primary or metastatic tumors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:68461 USPATFULL

TITLE: Human kininogen D3 domain polypeptide as an anti-angiogenic and anti-tumor agent

INVENTOR(S): Donate, Fernando, San Diego, CA, UNITED STATES
Mazar, Andrew P., San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005058599	A1	20050317	
	US 7098187	B2	20060829	
APPLICATION INFO.:	US 2003-661784	A1	20030915	(10)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: VENABLE, BAETJER, HOWARD AND CIVILETTI, LLP, P.O. BOX 34385, WASHINGTON, DC, 20043-9998
NUMBER OF CLAIMS: 42
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 2615
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 9 OF 19 USPATFULL on STN

TI Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof

AB The present invention relates generally to peptides, which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, methods of making peptides, which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, pharmaceutical compositions of these peptides and methods of using these peptides and pharmaceutical compositions of these peptides to treat diseases associated with aberrant vascularization.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:209805 USPATFULL

TITLE: Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof

INVENTOR(S): Allan, Amy L., Encinitas, CA, UNITED STATES
Donate, Fernando, San Diego, CA, UNITED STATES
Hopkins, Stephanie A., Poway, CA, UNITED STATES
Gladstone, Patricia L., San Diego, CA, UNITED STATES
Mazar, Andrew, San Diego, CA, UNITED STATES
O'Hare, Sean M., San Diego, CA, UNITED STATES
Parry, Graham, San Diego, CA, UNITED STATES
Plunkett, Marian, San Diego, CA, UNITED STATES
Ternansky, Robert J., San Diego, CA, UNITED STATES
Yoon, Won Hyung, San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004162239	A1	20040819	
APPLICATION INFO.:	US 2003-723144	A1	20031125	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2002-429174P	20021125	(60)
	US 2003-475539P	20030602	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: COOLEY GODWARD, LLP, 3000 EL CAMINO REAL, 5 PALO ALTO SQUARE, PALO ALTO, CA, 94306

NUMBER OF CLAIMS: 65
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 3373
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 10 OF 19 USPATFULL on STN
TI Novel antiangiogenic peptides, polypeptides encoding same and methods for inhibiting angiogenesis
AB Mammalian kringle 5 fragments and kringle 5 fusion proteins are disclosed as a compounds for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:178957 USPATFULL
TITLE: Novel antiangiogenic peptides, polypeptides encoding same and methods for inhibiting angiogenesis
INVENTOR(S): Davidson, Donald J., Gurnee, IL, UNITED STATES
Wang, Jieyi, Gurnee, IL, UNITED STATES
Gubbins, Earl J., Libertyville, IL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004138127	A1	20040715
APPLICATION INFO.:	US 2004-753646	A1	20040108 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1997-924287, filed on 5 Sep 1997, GRANTED, Pat. No. US 6699838 Continuation-in-part of Ser. No. US 1997-851350, filed on 5 May 1997, GRANTED, Pat. No. US 6057122 Continuation-in-part of Ser. No. US 1997-832087, filed on 3 Apr 1997, GRANTED, Pat. No. US 5981484 Continuation-in-part of Ser. No. US 1996-643219, filed on 3 May 1996, GRANTED, Pat. No. US 5801146
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEVEN F. WEINSTOCK, ABBOTT LABORATORIES, 100 ABBOTT PARK ROAD, DEPT. 377/AP6A, ABBOTT PARK, IL, 60064-6008
NUMBER OF CLAIMS: 68
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Page(s)
LINE COUNT: 3457
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 11 OF 19 USPATFULL on STN
TI Anthrax lethal factor inhibits tumor growth and angiogenesis
AB A method for inhibiting cell angiogenesis comprises contacting cells associated with undesired angiogenesis with an effective amount of an inhibitor of MEK or of an enzyme that is a member of the MAPK family. MEK inhibitors include MEK-directed proteases such as Bacillus anthracis lethal factor or a functional derivative thereof. Organic small molecule inhibitors of MEK include PD98059, U0126 and PD184352. The above contacting may be performed in vivo, in a human or other mammalian subject. Also included is a method to treat a mammalian subject having a disease or condition associated with undesired angiogenesis or neovascularization, comprising administering to the subject an effective amount of a pharmaceutical composition that comprises an inhibitor of MEK or of an enzyme that is a member of the MAPK family, as noted above, and pharmaceutically acceptable carrier or excipient. The treatment method is useful for a disease or condition such as tumor growth, tumor invasion or tumor metastasis, wherein the angiogenesis inhibition results in reduction in size or growth rate of the tumor or its destruction.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2004:177811 USPATFULL			
TITLE:	Anthrax lethal factor inhibits tumor growth and angiogenesis			
INVENTOR(S):	Duesbery, Nicholas S, Grand Rapids, MI, UNITED STATES Webb, Craig P, Grand Rapids, MI, UNITED STATES Vande Woude, George F, Ada, MI, UNITED STATES			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004136975	A1	20040715	
APPLICATION INFO.:	US 2004-472396	A1	20040308	(10)
	WO 2002-US8656		20020322	
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	VENABLE, BAETJER, HOWARD AND CIVILETTI, LLP, P.O. BOX 34385, WASHINGTON, DC, 20043-9998			
NUMBER OF CLAIMS:	29			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	4 Drawing Page(s)			
LINE COUNT:	2185			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 12 OF 19 USPATFULL on STN

TI Antiangiogenic peptides

AB Mammalian kringle 5 fragments and kringle 5 fusion proteins are disclosed as a compounds for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2004:53363 USPATFULL			
TITLE:	Antiangiogenic peptides			
INVENTOR(S):	Davidson, Donald J., Gurnee, IL, United States			
PATENT ASSIGNEE(S):	Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6699838	B1	20040302	
APPLICATION INFO.:	US 1997-924287		19970905	(8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-851350, filed on 5 May 1997, now patented, Pat. No. US 6057122 Continuation-in-part of Ser. No. US 1997-832087, filed on 3 Apr 1997, now patented, Pat. No. US 5981484 Continuation-in-part of Ser. No. US 1996-643219, filed on 3 May 1996, now patented, Pat. No. US 5801146			
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	GRANTED			
PRIMARY EXAMINER:	Low, Christopher S. F.			
ASSISTANT EXAMINER:	Robinson, Hope A.			
LEGAL REPRESENTATIVE:	Casuto, Dianne, Steele, Gregory W.			
NUMBER OF CLAIMS:	4			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	11 Drawing Figure(s); 11 Drawing Page(s)			
LINE COUNT:	3178			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 13 OF 19 USPATFULL on STN

TI Histidine proline rich glycoprotein (HPRG) as an anti-angiogenic and anti-tumor agent

AB Histidine Proline Rich Glycoprotein (HPRG) polypeptides or fragments thereof including pentapeptide fragments and multimers thereof, and other biologically active derivatives of HPRG are anti-angiogenic. These

compounds may be used to inhibit angiogenesis or treat a disease or condition in which angiogenesis is pathogenic. These compounds therefore have anti-tumor activity and are used in methods for inhibiting the growth of primary tumors or metastases. Antibodies specific for epitopes of the His-Pro rich domain of HPRG are stimulators of angiogenesis and are useful for promoting neovascularization in pertinent disease states.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:120259 USPATFULL			
TITLE:	Histidine proline rich glycoprotein (HPRG) as an anti-angiogenic and anti-tumor agent			
INVENTOR(S):	Donate, Fernando, San Diego, CA, UNITED STATES Harris, Scott, San Diego, CA, UNITED STATES Plunkett, Marian L., San Diego, CA, UNITED STATES Mazar, Andrew P., San Diego, CA, UNITED STATES			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003082740	A1	20030501	
APPLICATION INFO.:	US 2002-74225	A1	20020214	(10)
	NUMBER		DATE	
PRIORITY INFORMATION:	US 2001-268370P		20010214	(60)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	Venable, P.O. Box 34385, Washington, DC, 20043-9998			
NUMBER OF CLAIMS:	51			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	7 Drawing Page(s)			
LINE COUNT:	3231			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 14 OF 19 USPATFULL on STN

TI Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors

AB Modified peptide fragments of plasminogen domain are provided which exhibit anti-angiogenic activity. Compositions containing these peptide fragments and methods of using these compositions to treat angiogenic dependent and associated disorders are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:79063 USPATFULL			
TITLE:	Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors			
INVENTOR(S):	Ji, Weidong-Richard, Philadelphia, PA, UNITED STATES Meyers, Chester A., Medford, NJ, UNITED STATES Natarajan, Sesha I., Hillsborough, NJ, UNITED STATES Trail, Pamela A., Madison, CT, UNITED STATES			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003054988	A1	20030320	
APPLICATION INFO.:	US 2001-999457	A1	20011031	(9)
	NUMBER		DATE	
PRIORITY INFORMATION:	US 2000-245384P		20001102	(60)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000			
NUMBER OF CLAIMS:	10			
EXEMPLARY CLAIM:	1			

LINE COUNT: 557
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 15 OF 19 USPATFULL on STN
TI Antiangiogenic peptides and methods for inhibiting angiogenesis
AB Mammalian kringle 5 fragments are disclosed as a compounds for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2001:97890 USPATFULL
TITLE: Antiangiogenic peptides and methods for inhibiting angiogenesis
INVENTOR(S): Davidson, Donald J., Gurnee, IL, United States
PATENT ASSIGNEE(S): Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6251867	B1	20010626
APPLICATION INFO.:	US 1998-132154		19980811 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-132154, filed on 11 Aug 1998 And Ser. No. US 1997-832087, filed on 3 Apr 1997 Continuation-in-part of Ser. No. US 1996-643219, filed on 3 May 1996, now patented, Pat. No. US 5801146
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Hendricks, Keith D.
ASSISTANT EXAMINER: Stole, Einar
LEGAL REPRESENTATIVE: Steele, Gregory W., Casuto, Dianne
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 12 Drawing Page(s)
LINE COUNT: 2101
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 16 OF 19 USPATFULL on STN
TI Antiangiogenic peptides polynucleotides encoding same and methods for inhibiting angiogenesis
AB Mammalian kringle 5 fragments and kringle 5 fusion proteins are disclosed as a compounds for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2000:53906 USPATFULL
TITLE: Antiangiogenic peptides polynucleotides encoding same and methods for inhibiting angiogenesis
INVENTOR(S): Davidson, Donald J., Gurnee, IL, United States
PATENT ASSIGNEE(S): Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6057122		20000502
APPLICATION INFO.:	US 1997-851350		19970505 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-832087, filed on 3 Apr 1997 which is a continuation-in-part of Ser. No. US 1996-643219, filed on 3 May 1996, now patented, Pat. No. US 5801146
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wax, Robert A.
ASSISTANT EXAMINER: Stole, Einar

LEGAL REPRESENTATIVE: Steele, Gregory W., Casuto, Dianne
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 3215
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 17 OF 19 USPATFULL on STN
TI Antiangiogenic peptides and methods for inhibiting angiogenesis
AB Mammalian kringle 5 peptide fragments are disclosed for treating angiogenic diseases Methods and compositions for inhibiting angiogenic diseases are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 1999:141891 USPATFULL
TITLE: Antiangiogenic peptides and methods for inhibiting angiogenesis
INVENTOR(S): Davidson, Donald J., Gurnee, IL, United States
PATENT ASSIGNEE(S): Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5981484		19991109
APPLICATION INFO.:	US 1997-832087		19970403 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1996-643219, filed on 3 May 1996, now patented, Pat. No. US 5801146
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Prouty, Rebecca E.
ASSISTANT EXAMINER: Stole, Einar
LEGAL REPRESENTATIVE: Steele, Gregory W., Casuto, Dianne
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 12 Drawing Page(s)
LINE COUNT: 2474
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 18 OF 19 USPATFULL on STN
TI Antiangiogenic peptides and methods for inhibiting angiogenesis
AB Mammalian kringle 5 fragments are disclosed as a compounds for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 1999:132781 USPATFULL
TITLE: Antiangiogenic peptides and methods for inhibiting angiogenesis
INVENTOR(S): Davidson, Donald J., Gurnee, IL, United States
PATENT ASSIGNEE(S): Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5972896		19991026
APPLICATION INFO.:	US 1998-131995		19980811 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1997-832087, filed on 3 Apr 1997 which is a continuation-in-part of Ser. No. US 1996-643219, filed on 3 May 1996, now patented, Pat. No. US 5801146
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wax, Robert A.
ASSISTANT EXAMINER: Stole, Einar

LEGAL REPRESENTATIVE: Steele, Gregory W., Casuto, Dianne
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 12 Drawing Page(s)
LINE COUNT: 2444
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 19 OF 19 WPIDS COPYRIGHT 2007 THE THOMSON CORP on STN

TI Novel kringle 5 peptide compound or kringle 5 fusion protein, useful for inhibiting angiogenesis and thus for treating cancer, arthritis, macular degeneration and diabetic retinopathy

AN 2004-552394 [53] WPIDS

CR 1997-558670; 2000-349573; 2004-224006

AB US 20040138127 A1 UPAB: 20050706

NOVELTY - A kringle 5 peptide compound or kringle 5 fusion protein (I) which comprises amino acid residues 1-197 corresponding to sequence comprising amino acids 334-530 of a fully defined human plasminogen molecule (including its kringle 5 region) sequence (S1) of 791 amino acids as given in specification, and 1-12 amino acid residues corresponding to sequence from amino acid position 535-546 of (S1), is new.

DETAILED DESCRIPTION - A compound having the formula:

(a) A-B-C-X-Y (F1) or its salt, ester or prodrug, where A is absent or a nitrogen protecting group; Y is absent or a carboxylic acid protecting group; B is absent or is 1-197 naturally occurring amino acid residues corresponding to sequence from amino acid position 334-530 of (S1); C is R1-R2-R3-R4, where R1 is lysyl; R2 is leucyl or arginyl ; R3 is tyrosyl, 3-I-tyrosyl or phenylalanyl; R4 is aspartyl; and X is absent or is 1-12 naturally occurring amino acid residues corresponding to the sequence from amino acid position 535-546 of (S1) and their homologs or analogs; or

(b) A-B1-C1-X1-Y (F2) or its salt, ester or prodrug, where A and Y are as described above; B1 is absent or is 1-176 naturally occurring amino acid residues corresponding to the sequence from amino acid position 334-513 of (S1); C1 is the sequence from 514-523 amino acid position of (S1); and X1 is absent or is 1-10 naturally occurring amino acid residues corresponding to the sequence from amino acid position 524-533 of (S1) and their homologs or analogs.

The kringle 5 peptide fragment has substantially sequence homology to a plasminogen fragment chosen from human, murine, bovine, Rhesus monkey and porcine plasminogen.

INDEPENDENT CLAIMS are also included for the following:

(1) a composition (C1) comprising a mammalian isolated single- or double-stranded polynucleotide sequence (II) that encodes a kringle 5 peptide fragment or kringle 5 fusion protein having angiogenesis inhibiting activity;

(2) a composition (C2) comprising a kringle 5 peptide fragment or kringle 5 fusion protein and an excipient;

(3) (II) as described above;

(4) a vector (III) comprising (II);

(5) implanting into a human or non-human animal a cell containing a vector, where the vector contains (II) and where the vector is capable of expressing the kringle 5 peptide fragment or kringle 5 fusion protein when present in the cell;

(6) making a kringle 5 peptide fragment involves exposing a mammalian plasminogen to elastase at a ratio of 1:100-1:300 to form a mixture of the plasminogen of the elastase, incubating the mixture, and isolating the kringle 5 from the mixture; and

(7) making a soluble kringle 5 peptide fragment or kringle 5 fusion protein involves isolating a

polynucleotide which encodes the kringle 5 peptide fragment, cloning the polynucleotide into an expression vector, transforming the vector into a suitable host cell, and growing the host cell under conditions suitable for the expression of the soluble kringle 5 peptide fragment or kringle 5 fusion protein.

ACTIVITY - Cytostatic; Antiarthritic; Ophthalmological; Antipsoriatic; Antidiabetic; Antirheumatic; Antiinflammatory; Antiatherosclerotic; Dermatological; Vulnerary; Contraceptive.

MECHANISM OF ACTION - Angiogenesis inhibitor; Endothelial cell proliferation inhibitor; Ovulation inhibitor. The effect of kringle 5 peptide fragments on endothelial cell proliferation was determined in vitro using endothelial cell proliferation was assay. Kringle 5 peptide fragments were prepared and tested at various concentrations ranging from 100-1000 pm with basic fibroblast growth factor. The kringle 5 peptide fragment was effective at inhibiting bovine capillary (adrenal) endothelial cell (BCE) proliferation in a dose-dependent manner. The concentration of kringle 5 peptide fragment required to reach 50% inhibition (ED50) was determined at about 300 pM. In contrast, the ED50 of kringles 1-4 was shown to be 135 nM. The kringle 3 peptide fragment was least effective at inhibiting BCE cell proliferation (ED50 = 460 nM), followed by the kringle 1 peptide fragment (ED50 = 320 nM), kringle 1-4 peptide fragments (ED50 = 75 nM) and kringles 1-3 peptide fragments was the most effective at inhibiting BCE cell proliferation with an ED50 of 0.3.

USE - (I) (more preferably, human kringle 5 peptide fragment or kringle 5 fusion protein) is useful for treating a disease in a patient in need of antiangiogenesis therapy, preferably for treating cancer, arthritis, macular degeneration and diabetic retinopathy, more preferably cancer, metastatic solid tumors, carcinomas, sarcomas, lymphomas, psoriasis and hemangiomas (claimed). (I) is useful for treating primary and metastatic solid tumors and carcinomas of the breast, colon, rectum, lung, etc., and for prophylaxis of autoimmune diseases such as rheumatoid arthritis, retrolental fibroplasias, abnormal neovascularization conditions of the eye, Osler-Webber syndrome, myocardial angiogenesis; diseases characterized by abnormal stimulation of endothelia cells such as Crohn's disease, atherosclerosis, scleroderma and hypertrophic scars (that is keloids). (I) is also useful as a birth control agent which inhibits ovulation and establishment of the placenta. (I) is useful for preventing metastasis from tumors. (I) is useful as agonist or antagonist active at kringle 5 binding site, as antigens for developing specific antisera, as peptides for use in diagnostic kits, and as peptides linked to or used in combination with cytotoxic agents for targeted killing of cells that bind kringle 5 peptide fragments. (I) is also useful for isolating kringle 5 receptor. (III) is useful in gene therapy techniques for treating the above mentioned conditions.

ACCESSION NUMBER: 2004-552394 [53] WPIDS
CROSS REFERENCE: 1997-558670; 2000-349573; 2004-224006
DOC. NO. CPI: C2004-208850 [56]

TITLE: Novel kringle 5 peptide compound or kringle 5 fusion protein, useful for inhibiting angiogenesis and thus for treating cancer, arthritis, macular degeneration and diabetic retinopathy

DERWENT CLASS: A96; B04; D16

INVENTOR: DAVIDSON D J; GUBBINS E J; WANG J
PATENT ASSIGNEE: (DAVI-I) DAVIDSON D J; (GUBB-I) GUBBINS E J; (WANG-I) WANG J

COUNTRY COUNT: 1

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
US 20040138127	A1	20040715	(200453)*	EN	53	[7]

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 20040138127	A1 CIP of	US 1996-643219	19960503
US 20040138127	A1 CIP of	US 1997-832087	19970403
US 20040138127	A1 CIP of	US 1997-851350	19970505
US 20040138127	A1 Cont of	US 1997-924287	19970905
US 20040138127	A1	US 2004-753646	20040108

FILING DETAILS:

PATENT NO	KIND	PATENT NO
US 20040138127 A1	CIP of	US 5801146 A
US 20040138127 A1	CIP of	US 5981484 A
US 20040138127 A1	CIP of	US 6057122 A
US 20040138127 A1	Cont of	US 6699838 B

PRIORITY APPLN. INFO: US 2004-753646 20040108
US 1996-643219 19960503
US 1997-832087 19970403
US 1997-851350 19970505
US 1997-924287 19970905